oa South African Family Practice - Phosphodiesterase type 5 inhibitors and erectile dysfunction : CPD

Volume 52, Issue 3
  • ISSN : 2078-6190
  • E-ISSN: 2078-6204



Erectile dysfunction (ED) affects millions of men globally and may adversely affect his, and potentially his partners', quality of life. The introduction, a decade ago, of the phosphodiesterase type 5 (PDE5) inhibitors has revolutionised the management of ED. The PDE5 inhibitors have provided an effective and patient-acceptable therapy for ED. They have had a huge impact on public awareness and understanding of this disease. This article provides an overview of erectile dysfunction and the pharmacology, efficacy, safety and optimal use of the PDE5 inhibitors.

Loading full text...

Full text loading...


Article metrics loading...


This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error